Product Pipeline
Next Generation Peptide Cancer Immunotherapies
We develop two families of effective, low-cost, industrially scalable, rapidly delivered, off-the-shelf and personalized products without the need for tumor biopsy.
Treos’s differentiated technology provides substantial competitive advantages over all other approaches in the precision cancer vaccine field.
*Opportunity for co-development with novel CDx - assessed on a case-by case basis for each PolyPEPI product individually
PolyPEPI Off-the-shelf Peptide Cancer Vaccines
Off-the-shelf products contain 6-12 shared tumor antigen-derived peptides (PEPIs) optimized for a genetically broad population. Companion diagnostic tools (CDx) co-developed with each product identify likely responders.
Clinical trials conducted with our lead product, PolyPEPI1018, consistently confirmed exceptionally broad T cell responses correlating with clinical outcomes.
* OBERTO 101: NCT03391232 OBERTO 201: NCT05130060 OBERTO 301: NCT05243862
Personalized Peptide Cancer Vaccines
PEPI Panel – A unique approach to off-the-shelf personalized peptide immunotherapy design
Our Peptide Library (PEPI Panel) currently contains 3,286 proprietary, immunogenic peptide fragments from 184 tumor antigens associated with 19 cancer indications that induce immune responses in the largest subpopulation of subjects, based on HLA genotype (both class I and II) of 16,000 subjects. PEPI Panel approach guides selection of 12 individual peptides tailored to the tumor type and HLA genotype of patients from a warehouse of off-the-shelf peptides permitting the administration of personalized immunotherapy with unprecedently broad immunogenicity (Csiszovszki et al SITC 2019).
Proof-of-concept studies conducted with our personalized cancer imunotherapies demonstrated the unique precision of our technology: median 12 out of 12-13 individually selected peptides were immunogenic for the patient, post-treatment. Effector (Ex vivo) CD8+ T cell responses were detected up to 4 months and memory CD8+ T cell responses were detected up to 14 months after last vaccination, respectively (Somogyi et al ESMO2019).
PolyPEPI Preventive Vaccines against Infectious Diseases
Using our proprietary computational vaccine design technology, we have developed a PolyPEPI preventive peptide vaccine against COVID-19 (SARS-CoV-2).
The design of PolyPEPI-SCoV-2 exploits our knowledge on genetic heterogeneity of individuals and ethnicities. PolyPEPI-SCoV-2 vaccine can elicit broad and long-lasting immune responses in vaccinated subjects and can therefore protect people against COVID-19, worldwide. PolyPEPI-SCoV-2 contains 9 different peptide fragments from the four structural protein of the virus. Mutations of the virus will not affect the global coverage of our vaccine; the majority of subjects are expected to have a broad repertoire of virus-specific memory. Preclinical results support the use of our peptide vaccine also in post-exposure prophylaxis, as alternative vaccination strategy (Somogyi et al Front. Immunol 2023).
Intellectual Property
Subject Matter and IP status
Personalized Immunogenic Peptide Identification Platform
Published. Pending PCT application.
Regional applications filed in 50+ countries. Allowed in Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, South Korea, Singapore, South-Africa.
2 MAR 2018
Off-the-shelf, Population-based Immunogenic Peptide Identification Platform
Published. Pending PCT application.
Regional applications filed in 50+ countries. Allowed in China, Eurasian Patent Organization (Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia), Israel, Japan, South Korea, Singapore, South-Africa.
2 MAR 2018
“PEPI PANEL” Composition and Process for Selecting Peptides from PEPI PANEL Peptide Library for Off-the-shelf Personalized Cancer Treatments
Published. Pending PCT application. Regional applications filed in 50+ countries.
3 SEP 2019
“HLAT screening” Immunogenetic Cancer Screening Test Determining a Subject’s Risk of Developing Cancer
Published. Pending PCT application. Regional applications filed in 50+ countries. Allowed in Japan.
3 SEP 2019
Compositions of Colorectal-, Breast-, Ovarian cancers Off-the-shelf Peptide immunotherapies
Published. PolyPEPI1018 CRC immunotherapy granted (US PTO). Pending PCT application. Regional applications filed in 50+ countries. Allowed in USA, Colombia and Singapore.
2 MAR 2018
Compositions of Gastric-, Bladder-, Lung cancers & Melanoma Off-the-shelf Peptide Immunotherapies
Published. Pending PCT application. Regional applications filed in 50+ countries. Gastric peptide compositions allowed in USA and Saudi Arabia.
3 SEP 2019
Composition of coronavirus vaccine product
Published and allowed in USA, pending PCT application. Regional applications filed worldwide in 47 countries.
3 APR 2020